Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Lexicon Pharmaceuticals has reported that LX4211, an inhibitor of the sodium-dependent glucose transporter 2 (SGLT2; also known as SLC5A2), significantly improved glycaemic control in a Phase II ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) is associated with a lower mortality risk in older patients with advanced chronic kidney disease (CKD), according to data ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to ...

A comparison chart that includes competitor brands can be a tremendously effective addition to your product’s sales page. Introducing readers to other brands can be risky, especially if their ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an ...

In an emulated clinical trial that included a national cohort of veterans with both type 2 diabetes and CKD, SGLT2 inhibitor use was significantly associated with a lower risk for CKD progression.